Innate Pharma SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Innate Pharma SA Announces Details of Share Repurchase Program; Proposes No FY 2013 Dividend
Innate Pharma SA announced details of the share repurchase program which it will propose to its Annual General Meeting on June 28, 2013. The Company may repurchase a maximum of 10% of its own shares. The maximum price per share is EUR 10. The total maximum which may be spent on the program is EUR 10 million. If approved, the program will run for 18 months from the date of the Annual General Meeting. The Company also announced that it will not propose a dividend for fiscal year 2012. The Company did not pay a dividend for the three years preceding fiscal year 2012.
Latest Key Developments in Biotechnology
- Share this
- Digg this